These findings indicated that VEGF-C treatment increased the infiltration of CCR7+ immune cells, which contributed to the enhanced efficacy of anti-PD-1 immunotherapy and resulted in the inhibition of tumor progression. The gene discussed is VEGFC; the disease is neoplasm.